April 14, 2016 News by admin Array of Multiple Sclerosis Trial Data to Be Presented by Biogen at 2016 AAN Meeting A rangeĀ of new multiple sclerosis (MS) data from Biogen will be revealedĀ atĀ the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada, on April 15ā21. Presentations will include studies on TecfideraĀ (dimethyl fumarate),Ā one of the most frequently usedĀ oral MS treatments worldwide, as well as several other…
April 7, 2016 News by Patricia Silva, PhD Doctors Study Possible Link Between Dimethyl Fumarate (Tecfidera) and Shingles A case report of a woman with relapsing-remitting multiple sclerosis (RRMS) who developed shingles while being treated with dimethyl fumarate (Tecfidera) has raised questions of whether the drug reactivatesĀ the varicella-zoster virus. The study,Ā “Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate,“Ā was published in…
April 1, 2016 News by Patricia Silva, PhD MS Therapy Tecfidera Might Exert its Actions by Increasing Specific B-cells Editor’s note: The term B-cells is, in fact, a collective term for a group of cells having rather different properties. Some B-cells cells play a role in fighting invading pathogens or flawed cells, and can be wrongfully activated to target normal cells in autoimmune diseases. Regulatory B-cells (Bregs), instead act…
January 29, 2016 News by Charles Moore Multiple Sclerosis Patient and ‘Sopranos’ Actress Takes MS Struggle Public Millions of television viewers who watchedĀ the popularĀ HBO mob drama series “The Sopranos”Ā saw actress Jamie Lynn Sigler grow from a teen into a young woman as Meadow Soprano, theĀ independent-minded daughter of mafia boss Tony Soprano, played by the late James Gandolfini. This week, Sigler revealed she has been battling multiple…
January 27, 2016 News by Patricia Silva, PhD Tecfidera Seen to Alter Anti-Inflammatory Profile in Immune Cells Delayed-release dimethyl fumarate (Tecfidera) was recently approved for patients with relapsing-remitting multiple sclerosis (RRMS), although the mechanisms by which the drug exerts its action wereĀ not fully understood. A new study from the University Hospital MĆ¼nster, Germany, shows that dimethyl fumarate alters the balance between subpopulations of T-cells to promote…
December 28, 2015 News by Patricia Silva, PhD Top 10 Multiple Sclerosis Articles of 2015 Multiple Sclerosis News Today has reported the latest therapies, clinical trial developments, and events in multiple sclerosis (MS) on a daily basis throughout the past year. As 2015 comes to an end, hereĀ are the year’s 10 articlesĀ most widely readĀ byĀ Ā Multiple Sclerosis News TodayĀ readers, each with a brief summary of the developments…
December 18, 2015 News by Patricia Silva, PhD New MS Drug Therapy Based on Monomethyl Fumarate Moving Along in Testing Alkermes plc, a biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS) disorders, announced that it has successfully met its 2015 goals for their product and late-stage pipeline drug portfolio, including ALKS 8700, a monomethyl fumarate (MMF) drug candidate for the treatment of multiple sclerosis…
December 14, 2015 News by Patricia Silva, PhD 2 New Treatments for Relapsing-Remitting MS Now Available in New Zealand The Multiple Sclerosis Society of New Zealand (MSNZ)Ā announced thatĀ PHARMAC has agreed with its requestĀ toĀ finance two novel first-in-line therapies for relapsing-remitting forms of multiple sclerosis (MS), making them accessible to patients there. PHARMAC recently agreed to fund theĀ two treatments, teriflunomide (Aubagio), supplied by Sanofi-Aventis NZ, and dimethyl fumarate (Tecfidera),…
November 4, 2015 News by Patricia Silva, PhD Alkermes’ Multiple Sclerosis Therapy ALKS 8700 Yields Positive Clinical Trial Data Alkermes plc, a fully integrated global biopharmaceutical company, recently provided a regulatory update and positive clinical trial data for ALKS 8700, an oral, innovativeĀ and proprietary monomethyl fumarate (MMF) compound that is being developed to treat multiple sclerosis (MS). ALKS 8700 is being developed to quickly and efficiently convert…
October 22, 2015 News by Patricia Silva, PhD Biogen’s Investment in Multiple Sclerosis Therapies Reinforced in Company Restructuring Advancing key medicinal treatments likeĀ TECFIDERA (dimethyl fumarate), the most prescribed oral treatment for multiple sclerosis (MS), is a key focus of a company-wide restructuring recently announced byĀ Biogen, Inc.Ā TECFIDERA has been shown to reduce relapse rates, slow disability progression and the number of brain lesions in patients with relapsing forms…
October 9, 2015 News by Patricia Silva, PhD EXCLUSIVE: Top MS Researcher Gives Interview With MS News Today After Presenting New Data on Biogen’s TECFIDERA at #ECTRIMS2015 A top MS researcher for Biogen Idec answered questions in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros at a Satellite Symposia entitled āMS developments: transitioning evidence into clinical practiceā presentedĀ by the companyĀ this morning at the 31st Congress of the European Committee for Treatment and…
October 8, 2015 News by Patricia Silva, PhD Biogen to Present Update on TECFIDERA (Dimethyl Fumarate) for Early Stage Relapsing-Remitting Multiple Sclerosis at ECTRIMS 2015 Biogen is scheduled to present the latest efficacy and safety profile updates on TECFIDERA (dimethyl fumarate), its lead treatmentĀ forĀ relapsing-remitting multiple sclerosis (RRMS), during theĀ 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) happening now in Barcelona, Spain until October 10, 2015. The…
October 2, 2015 News by Patricia Silva, PhD Biogen to Present New Data at Upcoming ECTRIMS 2015 Congress on MS Therapies, Including TECFIDERA Biogen, a biotechnology company focused on innovative therapies for autoimmune disorders, neurodegenerative diseases and hematological conditions, recently announced that it will present new data on its multiple sclerosis (MS) portfolio of therapeutic agents at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis…
August 17, 2015 News by Patricia Silva, PhD Oral Disease Modifying Agents for Multiple Sclerosis Are Now More Preferred by Neurologists A survey of 97 neurologists conducted in June 2015 revealed specialists within the field of neurologyĀ are increasingly avoiding prescribing injectables to patients suffering from multiple sclerosis, as orally-available disease modifying-agents (DMAs) continue to gain in popularity. The survey was conducted and reported by Spherix Global Insights, a newly established business…
July 27, 2015 News by Charles Moore Biogen’s Tecfidera Now The Most Prescribed Oral MS Therapy Globally Cambridge, Massachusetts based Biogen Inc. has reported its second quarter 2015 results, posting a year-over-year seven percent revenue increase to $2.6 Billion in the quarter. āBiogen remains focused on improving the lives of people living with complex diseases,ā says Chief Executive Officer George A. Scangos, Ph.D. āTecfidera, which is now…
April 22, 2015 News by Patricia Silva, PhD Biogen To Present Data On The Effectiveness of TECFIDERA In Newly-Diagnosed MS Patients During The ANN Annual Meeting BiogenĀ hasĀ recently announced novelĀ results to support the effectiveness of TECFIDERAĀ (dimethyl fumarate) inĀ the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The results revealed that TECFIDERA significantly reduced disability progression andĀ relapses in RRMS patients who received their diagnosis for the first time and had a highly active form of the disease.Ā TECFIDERA…
October 9, 2014 News by Patricia Silva, PhD New Long-lasting Multiple Sclerosis Drug Will Come At a Steep Price Now more than ever, groundbreaking, new therapies for chronic diseases and infections come with high price tags. Earlier in the year, Gilead Sciences’ drugĀ Sovaldi for Hepatitis C, as well as Vertex’s Kalydeco for Cystic Fibrosis, both raised eyebrows over their cost. Now, a new MS therapy is doing the…
September 15, 2014 News by Patricia Silva, PhD Biogen Idec’s Study Reviews Positive Results Over Five Years of Tecfidera RRMS Treatment Biogen Idec presented theĀ five-year results from its ENDORSE phase 3 extension study of TecfideraĀ (dimethyl fumarate), which revealed that the treatment is able to provide strong and sustained efficacy to patients with relapsing-remitting multiple sclerosis (RRMS), at last week’sĀ ACTRIMS-ECTRIMSĀ summit. Not only did…
July 28, 2014 News by Patricia Silva, PhD Biogen Idec’s Injection Plegridy Approved in Europe to Treat RRMS The European Commission granted marketing authorization for the use of Plegridy, a drug developed by Biogen IdecĀ as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS),Ā the most common form of multiple sclerosis (MS). The approval comes at a time when…
July 22, 2014 News by Patricia Silva, PhD NICE Turns Back and Approves Biogenās Oral MS Drug Tecfidera in the UK The UK’s National Institute for Health and Care Excellence (NICE) gave a positive final appraisal determination to the use of the Biogen Idec‘s drugĀ Tecfidera (dimethyl fumarate) in adults for the treatment of relapsing-remitting multiple sclerosis (RRMS), having turned back on their preliminary negative recommendation. TheĀ oral…